Instadose Pharma EBIT

Instadose Pharma (INSD) currently reports a EBIT of $-1.7M as of February 2022. That compares with $-57K in the prior-year period — down 2896.7% year over year. That is below the sector sector average of $2.5T. Use the charts on this page to explore Instadose Pharma's EBIT history and peer comparisons.

Instadose Pharma's EBIT decreased from $-57K to $-1.7M — a 2896.7% year-over-year decrease (period ending February 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Instadose Pharma's EBIT of $-1.7M is lower than the its sector sector average of $2.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Instadose Pharma reported $-1.7M in EBIT as of February 2022. That compares with $-57K in the prior-year period — down 2896.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-1.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.5T. From there, open related valuation or income-statement pages for Instadose Pharma, and consider following INSD for alerts when major investors trade the stock.